Cochrane · systematic review · CD008830
Hormone replacement therapy for women previously treated for endometrial cancer
Edey, KA, Rundle, S, Hickey, M · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
2
No studies
3
Included studies
NR
No studies 3 · 60%Ungraded 0 · 0%Very low 2 · 40%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oestrogen replacement therapy compared to placebo for women previously treated for endometrial cancer
Population: women previously treated for endometrial cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Rate of symptom relief Oestrogen replacement therapy vs placebo | no estimate extracted | NR | No studies |
Rate of tumour recurrence Oestrogen replacement therapy vs placebo | RR 1.17 [0.54, 2.5] | 1 study · 1236 participants | Very low Downgraded: risk of bias |
Rate of appearance of a new malignancy Oestrogen replacement therapy vs placebo | RR 0.8 [0.32, 2.01] | 1 study · 1236 participants | Very low Downgraded: risk of bias |
Rate of survival: overall survival Oestrogen replacement therapy vs placebo | no estimate extracted | NR | No studies |
Rate of survival: progression‐free survival Oestrogen replacement therapy vs placebo | no estimate extracted | NR | No studies |